A. Yu. Polushin

A. Yu. Polushin

Auto-generated profile, based on publicly available information

A. Yu. Polushin

Pavlov University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2026 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Closed access
PDF file
VSV. A. Shurakova
V. A. Shurakova
AKAlexandr Nicolaevich Kulikov
Alexandr Nicolaevich Kulikov
APA. Yu. Polushin
A. Yu. Polushin
OGO. V. Galkina
O. V. Galkina
Anastasia Olegovna MedvedevaAnastasia Olegovna Medvedeva
Anastasia Olegovna Medvedeva
ABA. L. Bobrov
A. L. Bobrov
BACKGROUND . High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (AHSCT) is an effective treatment for resistant autoimmune diseases. However, the use of high-dose cyclophosphamide (CP) is associated with the risk of developing cyclophosphamide-induced cardiomyopathy (CIC). Massive infusion therapy may potentiate CP cardiotoxicity, but its role remains insufficiently studied. THE AIM : to assess the contribution of infusion load to the development of CP cardiomyopathy and to find an early signs of its development. PATIENTS AND METHODS . A prospective study was conducted involving 74 patients with multiple sclerosis receiving HDIT-AHSCT and 6 healthy volunteers. Comprehensive clinical, laboratory, and echocardiographic examinations were performed before, on the 3rd, and on the 7th day of therapy. RESULTS. In healthy individuals, infusions caused a transient elevation of NT-proBNP (max. 533.9 pg/ml) accompanied by an increase in heart chamber volumes and a rise in E/e'. Patients developed specific signs of cardiotoxicity: thickening of the walls and an increase in left ventricular (LV) myocardial mass. An NT-proBNP level >533.9 pg/ml on day 3 was associated with myocardial remodeling (ΔLV mass 15.94±26.36 g vs. -0.33±12.70 g, p=0.046) and left ventricular diastolic dysfunction (Δ E/e’ 1.21±2.10 vs. -0.19±1.39, p=0.030). Factor analysis identified three key components of cardiotoxicity, explaining 66.9% of the total data variance. CONCLUSION . Massive infusion therapy within the HDIT-AHSCT protocol is a significant factor potentiating CP cardiotoxicity. An NT-proBNP level >533.9 pg/ml and echocardiographic signs of remodeling on day 3 serve as early markers of cardiac damage. Awareness of the CF-induced cardiomyopathy early symptoms will help to accurate identification of high-risk patients for timely prevention.

11 October 2026 in New St. Petersburg Medical Records
Verified
Journal Article
Open access
PDF file
VSV. A. Shurakova
V. A. Shurakova
AKAlexandr Nicolaevich Kulikov
Alexandr Nicolaevich Kulikov
APA. Yu. Polushin
A. Yu. Polushin
YZYu. R. Zalyalov
Yu. R. Zalyalov
ELE. I. Lopatina
E. I. Lopatina
АЦА. А. Цынченко
А. А. Цынченко
Predictors of cardiomyopathy development in patients undergoing high-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation | Shurakova | New St. Petersburg Medical Records Предикторы развития кардиомиопатии у пациентов при высокодозной иммуносупрессивной терапии и аутологичной трансплантации гемопоэтических стволовых клеток | Шуракова | Новые Санкт-Петербургские врачебные ведомости